Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness and safety of LY4268989 combined with mirikizumab compared to mirikizumab alone in adults with moderately to severely active ulcerative colitis UC. This Phase 2, randomized, double-blind study focuses on treatment for UC, aiming to determine whether the combination improves clinical remission and response rates. Participants will receive either LY4268989 orally along with mirikizumab administered first intravenously then subcutaneously, or mirikizumab with a placebo oral treatment. Responders during the study will be re-randomized for a second study period. Treatment lasts approximately 104 weeks with up to 21 visits. Throughout the study, participants will attend regular visits for assessments including clinical remission status using the modified Mayo Score at weeks 12, 24, and 48, as well as endoscopic improvement and symptomatic remission. Safety and response to treatment will be monitored over about 118 weeks of total participation.
Actively Recruiting
Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.
Actively Recruiting
Researchers are evaluating the long-term safety, performance, and functional outcomes of the Indigo Aspiration System for treating pulmonary embolism PE. This observational study focuses on patients with acute PE and aims to gather real-world data on how well the device works and its safety over time. Participants receive frontline treatment with the Indigo Aspiration System as part of their standard care for acute PE. The study monitors patients for safety events within 48 hours after the procedure and assesses heart function by measuring the right ventricle to left ventricle ratio. Quality of life and functional outcomes are evaluated at 90 days, along with longer-term monitoring for serious device-related events and mortality up to one year and 30 days respectively. During the study, participants will undergo diagnostic imaging and clinical assessments to track their recovery and the effects of the device. Researchers will collect data on adverse events, quality of life questionnaires, exercise capacity tests, and symptom scales. The total participation lasts up to several months, including follow-up visits to ensure comprehensive monitoring of safety and function after treatment.